Skip to search formSkip to main contentSkip to account menu

MACOP-B regimen

Known as: Methotrexate-Adriamycin-Cytoxan-Oncovin-Prednisone-Bleomycin Regimen 
A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (6)

Antineoplastic Combined Chemotherapy ProtocolsBleomycinCyclophosphamideMethotrexate
DoxorubicinLeucovorin CalciumLymphoma, Non-HodgkinPrednisone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.
PURPOSE To investigate the incidence, natural history, and risk factors predictive of CNS relapse in patients with de novo… 
Review
2004
Review
2004
Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma.
BACKGROUND Optimal therapeutic management of intravascular lymphoma (IVL) lacks precise guidelines. PATIENTS AND METHODS The… 
Highly Cited
2004
Highly Cited
2004
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients
An extensive analysis of the reliability of positron emission tomography (PET) after induction treatment in patients with Hodgkin… 
Highly Cited
1997
Highly Cited
1997
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.
BACKGROUND We compared a regimen of six chemotherapeutic agents administered sequentially at high doses, followed by… 
Highly Cited
1993
Highly Cited
1993
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
BACKGROUND CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine… 
Highly Cited
1993
Highly Cited
1993
Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features.
PURPOSE To evaluate the clinical features of presentation, the morphologic and immunohistochemical pattern, the modality of… 
Highly Cited
1991
Highly Cited
1991
Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.
One hundred twenty-six patients with diffuse large-cell lymphoma were treated with methotrexate with leucovorin, doxorubicin… 
Highly Cited
1990
Highly Cited
1990
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
While diffuse large-cell lymphoma (DLCL) is considered to be highly curable with current therapy, treatment failures are observed… 
Highly Cited
1988
Highly Cited
1988
MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations.
Between 1981 and 1986, we treated 179 newly diagnosed patients with advanced-stage malignant lymphoma or related conditions with… 
Highly Cited
1985
Highly Cited
1985
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.
Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)